House passes bill that reauthorises the FDA’s paediatric priority voucher pathway
For Ilya Pharma, receiving a RPDD with PRV eligibility in 2024, this is a meaningful milestone providing security of a commercially viable development for our lead program developing ILP100-Topical as a limb saving treatment in children with the rare disease SAVI
Link to news reporting of the event: https://www.pharmaceutical-technology.com/news/house-passes-bill-that-reauthorises-the-fdas-paediatric-priority-voucher-pathway/#:~:text=Trials%20DACH%202026-,House%20passes%20bill%20that%20reauthorises%20the%20FDA